Johnson & Johnson and Pfizer Inc.’s bapineuzumab, an experimental drug that failed to help Alzheimer’s symptoms in a study, showed signs of reducing physical damage in the brain, according to a deeper analysis. Reisa Sperling, HMS professor of neurology at Brigham and Women’s Hospital, led one of the studies.
